IF YOU | AND | YOU ARE ELIGIBLE FOR |
| Have a first degree relative (mother, father, sister, brother, child) with type 1 diabetes | Are between ages 1 and 45 | Natural History Study of the Development of Type 1 Diabetes (TrialNet) |
| Have a second degree relative (cousin, uncle, aunt, niece, nephew, grandparent, or half-sibling) with type 1 diabetes | Are between ages 1 and 20 | Natural History Study of the Development of
Type 1 Diabetes (TrialNet)
|
| Have been diagnosed with type 1 diabetes within 3 months of study enrollment, and have one diabetes-related auto-antibodies present at screening | Are between ages 12 and 35 | T1DAL (Trial of Inducing Remission in New-Onset Type 1 Diabetes with Alefacept) This multicenter study is sponsored by the National Institute of Allergy and Infectious Diseases and is supported by the Juvenile Diabetes Research Foundation. It is investigating the effect of intramuscular injections of the protein alefacpt (Amevive®; Astellas Pharma US Inc.) on halting the destruction of beta cells in new-onset type 1 diabetes patients. Participants will receive weekly intramuscular injections of 15mg alefacept or placebo for two 12-week periods. If you are interested in participating in this study or would like to receive additional information, please call Carrie Gibson at (612) 624-5958 or email gibso002@umn.edu |
THESE STUDIES ARE NO LONGER ENROLLING
|
| Have had type 1 diabetes for less than 12 weeks | Are between ages 6 and 45 | Canakinumab Study- The Effects of Canakinumab on the Progression of Type 1 Diabetes in New Onset Subjects - No Longer Enrolling |
| Have had type 1 diabetes for less than 3 months | Are between ages 6 and 45 | CTLA 4 (Abatacept) New Onset Study - No Longer Enrolling |
| Have had type 1 diabetes for less than 90 days | Are between ages 12 and 45 | DEFEND-2: Phase 3 Trial of Otelixizumab for Young Adults With Newly Diagnosed Type 1 Diabetes Mellitus - No Longer Enrolling |
| Have had type 1 diabetes for less than 3 months | Are between ages 3 and 16 | Effects of Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) Formulated in Alum (GAD-alum) on the Progression of Type 1 Diabetes in New Onset Subjects (TrialNet) - No Longer Enrolling |
| Have type 1 diabetes | Are Mexican American or African American | The Genetics Study (TrialNet) - No Longer Enrolling |
| Have had Type 1 Diabetes for less than 3 months | Are between ages 8 and 45 | MMF/DZB - New Onset Study (TrialNet) - No Longer Enrolling |
Have a baby less than 5 months of age | The baby has a first degree relative with type 1 diabetes | Nutritional Intervention to Prevent Type 1 Diabetes Pilot Trial (TrialNet) - No Longer Enrolling |
Are a pregnant woman in your 3rd trimester | The expected baby has a first degree relative with type 1 diabetes | Nutritional Intervention to Prevent Type 1 Diabetes Pilot Trial (TrialNet) - No Longer Enrolling |
Have had type 1 diabetes for at least 2 weeks to 20 weeks | Are between the ages of 12 and 35 years | A Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PROCHYMAL™ (ex vivo cultured adult human mesenchymal stem cells) for the treatment of recently diagnosed type 1 diabetes mellitus (T1DM) - No Longer Enrolling
|
| Have had type 1 diabetes for less than 3 months | Are between ages 8 and 45 | Rituximab-New Onset Study (TrialNet) - No Longer Enrolling |
| Have had type 1 diabetes for less than 12 weeks | Are between ages 12 and 35 | Thymoglobulin (ATG) to Preserve Beta Cell Function in New Onset Type 1 Diabetes - No Longer Enrolling |
| Have had type 1 diabetes for less than 12 months | Are between ages 12 and 45 | TRX4 Therapeutic Evaluation of Different Multi-Dose Regimens in Type 1 Diabetes Mellitus (TTEDD) - No Longer Enrolling |
